Introduction The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …

Background Optimum management strategies for patients with advanced non-small-cell
lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are …

Inhibitors of the epidermal growth factor receptor (EGFR) are important treatment options for
non–small cell lung cancer (NSCLC) patients with activating EGFR mutations. Erlotinib …

Background: This meta-analysis evaluated the efficacy and toxicity of gefitinib with other
commonly used drugs in different treatment settings and epidermal growth factor receptor …

The objective of this study was to explore the relationship between gefitinib exposure and
clinical outcome in gefitinib-treated patients with advanced non-small cell lung cancer. Thirty …

PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …

Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …

Background Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)
readministration to lung cancer patients is common owing to the few options available …

Purpose A number of different clinical characteristics have been reported to singly correlate
with therapeutic activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …